Post-transplant maintenance care with chronic immunosuppression is necessary to prevent graft rejection; however, it imposes significant burdens on patients and the healthcare system alike. This highlights the unmet need for a therapeutic option with the goal of improving both long-term patient and graft survival, as well as quality-of-life outcomes.

A new, innovative approach to post–kidney transplant care utilizes FCR001, an investigational allogeneic cell therapy, to establish durable chimerism and drug-free immune tolerance in living-donor kidney transplant recipients across all degrees of human leukocyte antigen (HLA)-mismatch.

An expert panel will lead a discussion around the clinical consequences associated with the conventional, chronic immunosuppressive therapy utilized as standard of care post-transplant, the need for innovation and improved long-term outcomes in kidney transplant, as well as the potential of harnessing the power of induced tolerance with FCR001.

1. Introduce the potential of induced tolerance in the setting of kidney transplant via establishing persistent chimerism with FCR001 – an investigational allogeneic cell therapy
2. Describe the role of the Facilitating Cell in FCR001
3. Review long-term follow-up of a Phase 2 clinical trial to Induce tolerance in living-donor renal transplant recipients
4. Present the basic design of the FREEDOM-1 and FREEDOM-2 studies